drugset / Trial / NCT01302938

Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder

NCT01302938

Phase 4 Terminated 18 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the effect of tolterodine ER 4 mg to placebo on patient reported outcomes in subjects with overactive bladder after 1, 4, and 12 weeks of treatment using an innovative web-based trial design

Timeline

Start
2011-03
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolterodine Small molecule 4 mg Oral

Indications